965 related articles for article (PubMed ID: 8986946)
1. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
[TBL] [Abstract][Full Text] [Related]
2. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
3. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children.
Glikmann G; Petersen I; Mordhorst CH
Dan Med Bull; 1988 Apr; 35(2):185-7. PubMed ID: 3359817
[TBL] [Abstract][Full Text] [Related]
5. Humoral and cellular immune response after measles vaccination in Taiwan.
Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
[TBL] [Abstract][Full Text] [Related]
6. [Mumps epidemic in vaccinated children in West Switzerland].
Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D
Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835
[TBL] [Abstract][Full Text] [Related]
7. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
8. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
[TBL] [Abstract][Full Text] [Related]
9. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
Gonçalves G; Tavares F; de Andrade HR
Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
[TBL] [Abstract][Full Text] [Related]
10. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
11. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme.
Miller E; Waight P; Gay N; Ramsay M; Vurdien J; Morgan-Capner P; Hesketh L; Brown D; Tookey P; Peckham C
Commun Dis Rep CDR Rev; 1997 Feb; 7(2):R26-32. PubMed ID: 9046126
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines.
Ozaki K; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655
[TBL] [Abstract][Full Text] [Related]
14. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
15. [Changes in measles, mumps and rubella (MMR) immunity until the year of 2002 after the introduction of MMR vaccination].
Rønne T; Trier H
Ugeskr Laeger; 1992 Jul; 154(29):2014-8. PubMed ID: 1509567
[TBL] [Abstract][Full Text] [Related]
16. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B
Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126
[TBL] [Abstract][Full Text] [Related]
17. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
King SM; Saunders EF; Petric M; Gold R
Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
[TBL] [Abstract][Full Text] [Related]
18. Measles revaccination response in a school-age population.
Wittler RR; Veit BC; McIntyre S; Schydlower M
Pediatrics; 1991 Nov; 88(5):1024-30. PubMed ID: 1945606
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
[TBL] [Abstract][Full Text] [Related]
20. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
Narayan KM; Moffat MA
Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
